Interpreting SPRINT: How low should you go?

George Thomas^{1

2

3}, Joseph V Nally^{4

5}, Marc A Pohl^{6

7}

Affiliations

¹ Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Cleveland, OH, USA. E-mail: thomasg3@ccf.org.
² Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
³ Cleveland Clinic Site Principal Investigator, Systolic Blood Pressure Intervention Trial (SPRINT).
⁴ Director, Center for Chronic Kidney Disease, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁶ Ray W. Gifford Chair in Hypertension, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁷ Chair, Clinical Management Committee, Irbesartan Diabetic Nephropathy Trial.

PMID: 26974989
DOI: 10.3949/ccjm.83a.15175

Free article

Review

Interpreting SPRINT: How low should you go?

George Thomas et al. Cleve Clin J Med. 2016 Mar.

Free article

. 2016 Mar;83(3):187-95.

doi: 10.3949/ccjm.83a.15175.

Authors

George Thomas^{1

2

3}, Joseph V Nally^{4

5}, Marc A Pohl^{6

7}

Affiliations

¹ Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Cleveland, OH, USA. E-mail: thomasg3@ccf.org.
² Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
³ Cleveland Clinic Site Principal Investigator, Systolic Blood Pressure Intervention Trial (SPRINT).
⁴ Director, Center for Chronic Kidney Disease, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁶ Ray W. Gifford Chair in Hypertension, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁷ Chair, Clinical Management Committee, Irbesartan Diabetic Nephropathy Trial.

PMID: 26974989
DOI: 10.3949/ccjm.83a.15175

Abstract

The Systolic Blood Pressure Intervention Trial (SPRINT) found evidence of cardiovascular benefit with intensive lowering of systolic blood pressure (goal < 120 mm Hg) compared with the currently recommended goal (< 140 mm Hg) in older patients with cardiovascular risk but without diabetes or stroke. This article reviews the trial design and protocol, summarizes the results, and briefly discusses the implications of these results.

PubMed Disclaimer

Comment in

To the Editor: Blood pressure targets.
Yilmaz Ö. Yilmaz Ö. Cleve Clin J Med. 2016 Jul;83(7):487. doi: 10.3949/ccjm.83c.07001. Cleve Clin J Med. 2016. PMID: 27399856 No abstract available.
To the Editor: Blood pressure targets.
Edwards JL. Edwards JL. Cleve Clin J Med. 2016 Jul;83(7):487-8. doi: 10.3949/ccjm.83c.07002. Cleve Clin J Med. 2016. PMID: 27399857 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Interpreting SPRINT: How low should you go?

Affiliations

Interpreting SPRINT: How low should you go?

Authors

Affiliations

Abstract

Comment in

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical